1
|
Hazim AZ, Ruan GJ, Hu M, Ravindran A, Rech KL, Young JR, Cox CW, Abeykoon JP, Scheckel C, Vassallo R, Ryu JH, Tobin WO, Koster MJ, Bennani NN, Shah MV, Goyal G, Go RS. Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival. Am J Hematol 2021; 96:1604-1610. [PMID: 34553412 DOI: 10.1002/ajh.26355] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 09/14/2021] [Accepted: 09/20/2021] [Indexed: 01/20/2023]
Abstract
Langerhans cell histiocytosis (LCH) is a histiocytic neoplasm that can involve the lungs as single system (LCH-SSL) or multisystem disease (LCH-MSL). The role of full-body radiographic staging to determine whether patients have LCH-SSL or LCH-MSL is unclear. Long-term outcomes of LCH-SSL versus LCH-MSL and multisystem without lung involvement (LCH-MSNL) are unknown. A retrospective study of adult LCH patients seen at our center from January 2000 to 2020 was performed. In Part 1, we addressed utility of whole-body staging imaging among those presenting with isolated pulmonary signs or symptoms. Staging was defined as fluorodeoxyglucose positron emission tomography-computed tomography (CT) or whole-body CT obtained within 3 months of diagnosis. In Part 2, we examined the frequency of developing extra-pulmonary disease over time and mortality in patients with LCH-SSL. In Part 3, we compared the overall survival of LCH-SSL, LCH-MSL, and LCH-MSNL. Part 1: 240 patients with LCH were identified. A total of 112 (47%) had pulmonary signs or symptoms at presentation. Thirty-four (30%) underwent radiographic staging and only one showed evidence of extra-pulmonary disease. Part 2: 108 (45%) were LCH-SSL. Median follow-up duration of 4.5 years (95% confidence interval [CI]: 2.9-6.0). None developed extra-pulmonary disease. Part 3: 5-year survival: 94% (95% CI: 84%-98%) for LCH-SSL, 78% (95% CI: 59%-90%) for LCH-MSL, and 75% (95% CI: 53%-89%) for LCH-MSNL. LCH patients presenting with isolated pulmonary signs or symptoms rarely have extra-pulmonary involvement at the time of diagnosis and generally do not develop extra-pulmonary progression. LCH-SSL has the best overall survival, while LCH-MSL and LCH-MSNL have similar clinical outcomes.
Collapse
Affiliation(s)
| | - Gordon J. Ruan
- Division of Hematology Mayo Clinic Rochester Minnesota USA
| | - Marie Hu
- Division of Hematology‐Oncology University of Minnesota Minneapolis Minnesota USA
| | - Aishwarya Ravindran
- Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA
| | - Karen L. Rech
- Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA
| | - Jason R. Young
- Department of Radiology Mayo Clinic Rochester Minnesota USA
| | | | | | - Caleb Scheckel
- Division of Hematology Mayo Clinic Rochester Minnesota USA
| | - Robert Vassallo
- Division of Pulmonary and Critical Care Medicine Mayo Clinic Rochester Minnesota USA
| | - Jay H. Ryu
- Division of Pulmonary and Critical Care Medicine Mayo Clinic Rochester Minnesota USA
| | | | | | | | - Mithun V. Shah
- Division of Hematology Mayo Clinic Rochester Minnesota USA
| | - Gaurav Goyal
- Division of Hematology‐Oncology University of Alabama at Birmingham Birmingham Alabama USA
- Research Collaborator (limited‐tenure), Mayo Clinic Rochester Minnesota USA
| | - Ronald S. Go
- Division of Hematology Mayo Clinic Rochester Minnesota USA
| | | |
Collapse
|
2
|
Duquenne JB, Duysinx B, Radermecker M, Nchimi A, Louis R, Guiot J. [Cystic lung diseases]. Rev Mal Respir 2021; 38:257-268. [PMID: 33707116 DOI: 10.1016/j.rmr.2021.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Accepted: 01/02/2021] [Indexed: 11/29/2022]
Abstract
Cystic lung diseases present uncommonly and have an undetermined incidence. Cysts result from a broad spectrum of causative mechanisms and diseases leading to variable clinical presentations. The pathogenic mechanisms that can lead to lung cyst formation include infection, neoplastic, systemic, traumatic, genetic and congenital processes. A rigorous, systemic and multidisciplinary approach is advised in the diagnostic workup of these conditions. In this article, we review cystic lung diseases including their presentation and management.
Collapse
Affiliation(s)
- J-B Duquenne
- Service de pneumologie, CHU Liège, Liège, Belgique.
| | - B Duysinx
- Service de pneumologie, CHU Liège, Liège, Belgique
| | - M Radermecker
- Service de chirurgie thoracique, CHU Liège, Liège, Belgique
| | - A Nchimi
- Service de radiologie, CH de Luxembourg ville, Luxembourg, Luxembourg
| | - R Louis
- Service de pneumologie, CHU Liège, Liège, Belgique
| | - J Guiot
- Service de pneumologie, CHU Liège, Liège, Belgique
| |
Collapse
|
3
|
Perriot J, Underner M, Peiffer G, Arvers P. [Smoking cessation in smokers with pulmonary Langerhans cell histiocytosis - considerations from the management of ten patients]. Rev Mal Respir 2021; 38:157-163. [PMID: 33516597 DOI: 10.1016/j.rmr.2020.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 10/17/2020] [Indexed: 02/05/2023]
Abstract
Pulmonary Langerhans cell histiocytosis (PLCH) belongs to the spectrum of diffuse interstitial cystic pneumonias; it affects young people of both sexes and occurs almost exclusively in tobacco smokers or co-users of tobacco and cannabis. The management of this severe chronic disease is undertaken in specialized centers. A better understanding of the pathogenic mechanisms of the disease has opened up prospects for targeted therapies. However, supporting the abstinence from inhaling noxious materials which determine its prognosis remains the cornerstone of treatment. Patients with PLCH who persist in smoking despite the diagnosis may be very dependent on tobacco, experience significant difficulties in stopping smoking, and must have access to specialist smoking cessation clinics.
Collapse
Affiliation(s)
- J Perriot
- Dispensaire Emile Roux. Centre de tabacologie et Centre de lutte antituberculeuse (CLAT 63), 11, rue Vaucanson 63100 Clermont-Ferrand, France.
| | - M Underner
- Unité de recherche clinique, Centre Hospitalier Henri-Laborit, Université de Poitiers, 86021 Poitiers, France
| | - G Peiffer
- Service de pneumologie, CHR de Metz-Thionville, 57038 Metz, France
| | - P Arvers
- Hôpital de la Croix-Rousse, Institut Rhône-Alpes-Auvergne de Tabacologie (IRAAT), Hôpital de la Croix- Rousse, 69004 Lyon, France
| |
Collapse
|
4
|
Ropars C, Kerjouan M, Larible C, Llamas Gutierrez F, Léderlin M, De Latour B, Desrues B, Jouneau S. [Lung metastases of pancreatic adenocarcinoma: Watch for the second train!]. Rev Mal Respir 2019; 36:738-741. [PMID: 31230848 DOI: 10.1016/j.rmr.2019.04.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Accepted: 04/11/2019] [Indexed: 01/15/2023]
Abstract
Pulmonary metastases due to a pancreatic cancer are difficult to diagnose and demonstrate a wide range of radiological patterns. We report the case of a 37-year-old female patient, without past medical history, with multicystic lung disease in a context of chronic abdominal pain, fatigue and weight loss. After several months of diagnostic delay, pathological examination of surgical lung biopsies led to the diagnosis of secondary deposits of pancreatic cancer. The clinical and radiogical situation deteriorated quickly with the development of alveolar consolidation and Aspergillus superinfection was then diagnosed. This case illustrates the value of an early decision to undertake surgical lung biopsy in the work-up of multicystic lung disease when cancer is suspected. In addition, in the specific context of cancer, faced with clinical and/or radiological deterioration, it is essential to look for infection, particularly aspergillosis.
Collapse
Affiliation(s)
- C Ropars
- Service de pneumologie, hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France.
| | - M Kerjouan
- Service de pneumologie, hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France
| | - C Larible
- Service d'oncologie médicale, centre Eugène-Marquis, avenue de la Bataille Flandres-Dunkerque, 35042 Rennes cedex, France
| | - F Llamas Gutierrez
- Service d'anatomopathologie, hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France
| | - M Léderlin
- Service de radiologie, hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France; LTSI, Inserm U1099, université de Rennes 1, 2, avenue du Pr Léon-Bernard, 35043 Rennes, France
| | - B De Latour
- Service de chirurgie thoracique et cardiovasculaire, université de Rennes 1, hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France
| | - B Desrues
- Service de pneumologie, hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France; Université de Rennes 1, 2, avenue du Pr Léon-Bernard, 35043 Rennes, France
| | - S Jouneau
- Service de pneumologie, hôpital Pontchaillou, 2, rue Henri-Le-Guilloux, 35033 Rennes cedex 9, France; Irset UMR 1085, université de Rennes 1, 2, avenue du Pr Léon-Bernard, 35043 Rennes, France
| |
Collapse
|
5
|
Sevrage tabagique et histiocytose pulmonaire langerhansienne : à propos de 5 cas pris en charge en centre de tabacologie. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
6
|
Coudert P. Cancers cutanés et chimiothérapie. ACTUALITES PHARMACEUTIQUES 2018. [DOI: 10.1016/j.actpha.2018.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
7
|
Benzaquen J, Pradelli J, Padovani B, Marquette CH, Leroy S. [Emphysema, did you say emphysema?]. Rev Mal Respir 2018; 35:83-87. [PMID: 29402641 DOI: 10.1016/j.rmr.2017.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2017] [Accepted: 06/20/2017] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a common condition that may initially look simple but may conceal other diseases capable of accelerating its natural history or even simulating it. We describe four cases presenting as COPD with emphysema that were reclassified on the basis of certain clinical characteristics and the radiological pattern. CASE REPORTS A 52 year old never smoking woman presenting with emphysema was eventually diagnosed as having lymphangioleiomyomatosis on the basis of an abdominal CT scan showing kidney angiomyolipomas. A 44 years old smoker presenting with rapidly evolving emphysema was eventually diagnosed as having Langerhans cell histiocytosis on the basis of a previous chest CT (four years earlier) showing cavitating nodules. An airport refueler, 73 years old, with severe emphysema despite never having smoked, was eventually diagnosed as suffering from alpha-1 antitrypsin deficiency. The last patient was a 54 year old man, a never smoker, who presented with severe airflow limitation and multilobar hyperlucency, with bronchiectasis in the same areas. He was eventually diagnosed as having a severe form of the Swyer-James-MacLeod syndrome. CONCLUSION These four case reports underline the importance of questioning the diagnosis of COPD when certain particular phenotypic characteristics are identified.
Collapse
Affiliation(s)
- J Benzaquen
- Service de pneumologie, hôpital Pasteur, universite Côte-d'Azur, FHU OncoAge, centre hospitalier universitaire de Nice, 06000 Nice, France.
| | - J Pradelli
- Service de pneumologie, hôpital Pasteur, universite Côte-d'Azur, FHU OncoAge, centre hospitalier universitaire de Nice, 06000 Nice, France
| | - B Padovani
- Service de radiologie, universite Côte-d'Azur, FHU OncoAge, CHU de Nice, 06000 Nice, France
| | - C H Marquette
- Service de pneumologie, hôpital Pasteur, universite Côte-d'Azur, FHU OncoAge, centre hospitalier universitaire de Nice, 06000 Nice, France
| | - S Leroy
- Service de pneumologie, hôpital Pasteur, universite Côte-d'Azur, FHU OncoAge, centre hospitalier universitaire de Nice, 06000 Nice, France
| |
Collapse
|
8
|
Sajiai H, Rachidi M, Serhane H, Aitbatahar S, Amro L. [Pulmonary Langerhans' cell histiocytosis (PLCH) revealed by pneumothorax: about a case]. Pan Afr Med J 2017; 25:32. [PMID: 28154724 PMCID: PMC5268801 DOI: 10.11604/pamj.2016.25.32.10356] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 08/04/2016] [Indexed: 12/03/2022] Open
Abstract
L’histiocytose langerhansienne est une affection rare d’étiologie inconnue caractérisée par une infiltration d’un ou plusieurs organes, par des cellules de type Langerhans. Elle a une présentation clinique polymorphe. Nous rapportons le cas de Mr R.Y, âgé de 22 ans, tabagique à 8 PA, admis pour pneumothorax total spontané droit. Un drainage thoracique a été réalisé avec bonne évolution. La TDM thoracique de contrôle a objectivé de multiples formations kystiques diffuses prédominant aux lobes supérieurs. Un bilan a été réalisé à la recherche d’une histiocytose systémique mais s’est révélé négatif. L’évolution était marquée par la récidive du pneumothorax, le recours à une pleurodèse et la réalisation d’une biopsie pulmonaire qui a confirmé le diagnostic. Le diagnostic de l’HistiocytoseLangerhansienne doit être évoqué devant un pneumothorax sur poumon kystique. Le diagnostic est aisé devant un tableau clinique et radiologique évocateur. Néanmoins, les possibilités thérapeutiques restent limitées et la récidive du pneumothorax est fréquente.
Collapse
Affiliation(s)
- Hafsa Sajiai
- Service de Pneumologie, Hôpital Arrazi, CHU Mohamed VI, Laboratoire PCIM, UCAM, Marrakech, Maroc
| | - Mariam Rachidi
- Service de Pneumologie, Hôpital Arrazi, CHU Mohamed VI, Laboratoire PCIM, UCAM, Marrakech, Maroc
| | - Hind Serhane
- Service de Pneumologie, Hôpital Arrazi, CHU Mohamed VI, Laboratoire PCIM, UCAM, Marrakech, Maroc
| | - Salma Aitbatahar
- Service de Pneumologie, Hôpital Arrazi, CHU Mohamed VI, Laboratoire PCIM, UCAM, Marrakech, Maroc
| | - Lamyae Amro
- Service de Pneumologie, Hôpital Arrazi, CHU Mohamed VI, Laboratoire PCIM, UCAM, Marrakech, Maroc
| |
Collapse
|
9
|
Rolland-Debord C, Fry S, Giovannelli J, Langlois C, Bricout N, Aguilaniu B, Bellocq A, Le Rouzic O, Dominique S, Delobbe A, François G, Tazi A, Wallaert B, Chenivesse C. Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis. PLoS One 2017; 12:e0170035. [PMID: 28072848 PMCID: PMC5225005 DOI: 10.1371/journal.pone.0170035] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2016] [Accepted: 12/27/2016] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Reduced exercise capacity severely impacts quality of life in pulmonary Langerhans cell histiocytosis. Ascertaining mechanisms that impair exercise capacity is necessary to identify targets for symptomatic treatments. METHODS Dyspnea, pulmonary function tests and cardiopulmonary exercise test were analysed in 62 study participants. Data were compared between subjects with impaired and normal aerobic capacity (V'O2 peak less than 84% versus 84% predicted or more). Data were reduced using a principal component analysis. Multivariate analysis included V'O2 peak as the dependent variable and principal components as covariates. RESULTS V'O2 peak was reduced in 44 subjects (71%). Subjects with impaired aerobic capacity presented: (i) decreased FEV1, FVC, FEV1/FVC, DLCO and DLCO/VA and increased AaDO2, (ii) increased ventilatory equivalents at ventilatory threshold, VD/VT peak, AaDO2 peak and PaCO2 peak and decreased ventilatory reserve and PaO2 peak. There was no difference between groups in dyspnea scores. Principal component analysis extracted 4 principal components interpreted as follows: PC1: gas exchange; PC2: "pseudorestriction"; PC3: exercise-induced hyperpnea; PC4: air trapping. Multivariate analysis explained 65% of V'O2 peak. The 4 principal components were independently associated with V'O2 peak (βcoefficients: PC1: 9.3 [4.6; 14], PC2: 7.5 [3; 11.9], PC3: -5.3 [-9.6;-1.], PC4: -9.8 [-14,9;-4.7]). CONCLUSION Impaired exercise capacity is frequent in pulmonary Langerhans cell histiocytosis. It is mainly caused by pulmonary changes but is not associated with increased dyspnea intensity. Therefore, treating the lung represents a relevant approach for improving exercise capacity, even in patients experiencing mild dyspnea.
Collapse
Affiliation(s)
- Camille Rolland-Debord
- Service de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France
- Service de Pneumologie et Réanimation médicale, APHP-Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Paris, France
- UMRS 1158 Neurophysiologie respiratoire expérimentale et clinique, Sorbonne Universités, UPMC Univ Paris 06, INSERM, Paris, France
| | - Stephanie Fry
- Service de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France
| | - Jonathan Giovannelli
- Pôle de Santé Publique, Pharmacie et Pharmacologie, CHU Lille, Univ. Lille, Lille, France
| | - Carole Langlois
- Service de Biostatistiques, CHU Lille, Univ. Lille, Lille, France
| | - Nicolas Bricout
- Service de Radiologie, CHU Lille, Univ. Lille, Lille, France
| | | | - Agnes Bellocq
- UMRS 1158 Neurophysiologie respiratoire expérimentale et clinique, Sorbonne Universités, UPMC Univ Paris 06, INSERM, Paris, France
- Service d’Explorations Fonctionnelles de la Respiration, de l’Exercice et de la Dyspnée, APHP-Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Paris, France
| | - Olivier Le Rouzic
- Service de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France
| | - Stephane Dominique
- Clinique Pneumologique, Hôpital Charles Nicolle, Université de Rouen, Centre Hospitalier Universitaire de Rouen, Rouen, France
| | - Alain Delobbe
- Service de Pneumologie, Centre Hospitalier Régional de la citadelle, Liège, Belgique
| | - Geraldine François
- Service de Pneumologie et Réanimation, Centre Hospitalier Universitaire d’Amiens, Université de Picardie Jules Verne, Amiens, France
| | - Abdellatif Tazi
- Service de Pneumologie, Centre de Référence de l’Histiocytose Langerhansienne, APHP - Hôpital Saint-Louis, Université Paris-Diderot, Sorbonne Paris Cité; INSERM UMR 1153 CRESS, Equipe de Recherche en Biostatistiques et Epidémiologie Clinique, Paris, France
| | - Benoit Wallaert
- Service de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France
| | - Cecile Chenivesse
- Service de Pneumologie et ImmunoAllergologie, Centre de Compétence des Maladies Pulmonaires Rares, CHU Lille, Univ. Lille, Lille, France
| |
Collapse
|
10
|
|